Details of the Drug

General Information of Drug (ID: DMHQKN6)

Drug Name
CART-19
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 2 [2]
B-cell chronic lymphocytic leukaemia 2A82.00 Phase 1 [1]
B-cell lymphoma 2A86 Phase 1 [3]
Diffuse large B-cell lymphoma 2A81 Phase 1 [1]
Follicular lymphoma 2A80 Phase 1 [1]
Haematopoietic/lymphoid cancer 2B33.5 Phase 1 [1]
leukaemia 2A60-2B33 Phase 1 [3]
Mantle cell lymphoma 2A85.5 Phase 1 [1]
Prolymphocytic leukaemia 2A82.1 Phase 1 [1]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0G4IW
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
2 ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
3 ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma